Stockreport

Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease

Hepion Pharmaceuticals, Inc.  (HEPA) 
Last hepion pharmaceuticals, inc. earnings: 11/14 05:17 pm Check Earnings Report
PDF - Demonstrated improvements among best reported of fibrosis-reducing compounds - - Liver stiffness results complemented by positive changes in disease biomarkers an [Read more]